TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06297642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 injection
Description: Anti-CD47 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study: NCT06671106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flossing
Description: dental floss (meridol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flossing
Description: dental floss (meridol)

Intervention type: OTHER
Group type: OTHER
Intervention: flossing
Description: dental floss (meridol)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste Product
Description: amine and zinc lactate - containing toothpaste (meridol Gum Protection)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothpaste Product
Description: amine and zinc lactate - containing toothpaste (meridol Gum Protection)
Study: NCT06671106

Intervention type: DEVICE
Group type: OTHER
Intervention: Toothpaste Product
Description: amine and zinc lactate - containing toothpaste (meridol Gum Protection)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthrinse
Description: amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
Study: NCT04983927

Intervention type: DEVICE
Intervention: cASPECTS
Description: Clinical decision support system for scoring ASPECTS score

Intervention type: DEVICE
Intervention: cASPECTS
Description: Clinical decision support system for scoring ASPECTS score

Intervention type: DEVICE
Intervention: cASPECTS
Description: Clinical decision support system for scoring ASPECTS score
Study: NCT05245266

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Redraw for analysis of blood samples from healthy pregnant women
Description: If less than two fetal cells are recovered from maternal blood, a redraw is indicated
Study: NCT04956068

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
Study: NCT05056363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Traditional Scoliosis Exercises
Description: Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Traditional Scoliosis Exercises
Description: Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Training
Description: Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
Study: NCT05470530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
Study: NCT05589129

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Supplement
Description: Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Placebo Control
Description: Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
Study: NCT06393504

Intervention type: DRUG
Intervention: Daridorexant
Description: Daridorexant received during or shortly prior to pregnancy.

Intervention type: DRUG
Intervention: Non-orexin receptor antagonist insomnia medication
Description: Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.

Intervention type: OTHER
Intervention: No insomnia medication
Description: No insomnia medication received during or shortly prior to pregnancy.
Study: NCT06124859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional capacity tests
Description: Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)
Study: NCT05492396

Intervention type: DEVICE
Intervention: Standard gluteus medius repair with Tapestry Biointegrative implant
Description: Patients will undergo standard gluteus medius repair utilizing augmentation.
Study: NCT05754177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive an equivalent placebo for 84 days.
Study: NCT04745910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Given IV
Study: NCT05989386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Description: During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine Swab
Description: No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
Study: NCT04998825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proteoglycan F
Description: Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
Study: NCT05235815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retro SCTL compartment block
Description: For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4).
Study: NCT06727123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No application will be made. Routine follow-ups will be made.
Study: NCT05828277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repotrectinib (TPX-0005)
Description: Oral repotrectinib (TPX-0005)
Study: NCT06441734

Intervention type: DIAGNOSTIC_TEST
Intervention: cbc serum ferritin serum iron
Description: by using sample of blood to do cbc and serum ferritin and serum iron during 1year

Intervention type: DIAGNOSTIC_TEST
Intervention: cbc serum ferritin serum iron
Description: by using sample of blood to do cbc and serum ferritin and serum iron during 1year
Study: NCT06391866

Intervention type: OTHER
Intervention: extracorporeal circulation
Description: extracorporeal circulation during cardiosurgical operation

Intervention type: OTHER
Intervention: extracorporeal circulation
Description: extracorporeal circulation during cardiosurgical operation
Study: NCT05026216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qwo
Description: Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
Study: NCT05755672

Intervention type: DRUG
Intervention: Chemotherapy
Description: Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines

Intervention type: PROCEDURE
Intervention: Resection of the primary tumor
Description: Surgical resection of the primary tumour, according to the current clinical practice guidelines

Intervention type: PROCEDURE
Intervention: Resection of tumour metastases
Description: Surgical resection of tumour metastases, according to the current clinical practice guidelines

Intervention type: PROCEDURE
Intervention: Blood sampling during chemotherapy
Description: Drawing of blood samples several times during patient visits for chemotherapy regimen
Study: NCT05367544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-Level Peer Support
Description: Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Level Peer Support
Description: Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-Level Peer Support
Description: Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
Study: NCT06464562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiveWell: Adapted Dialectical Behavioral Therapy Skills Training
Description: An adapted dialectical behavioral therapy skills training intervention
Study: NCT03601702

Intervention type: DEVICE
Intervention: Mechanical thrombectomy with EmboTrap ® II Device
Description: Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
Study: NCT06433089

Intervention type: PROCEDURE
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block was performed before surgery
Study: NCT05681494

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy
Description: exposed pulp will be capped with 3 mm calcium silicate material
Study: NCT05630677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 solution for infusion
Description: Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 oral suspension
Description: Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 film-coated tablet
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 film-coated tablet
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 film-coated tablet
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 film-coated tablet
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, Delayed-release tablet
Description: Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, Delayed-release tablet
Description: Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
Study: NCT06393166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
Description: Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
Study: NCT05266677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blend of glycerides at certain proportions
Description: combination of glycerides in specific proportions in a liquid oral supplement

Intervention type: OTHER
Group type: OTHER
Intervention: glycerides used in current formulas
Description: glycerides used in current formulas in a liquid oral supplement
Study: NCT05156346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAVES
Description: LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
Study: NCT05741112

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
Study: NCT05535413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTD1 combined with capecitabine
Description: UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle.
Study: NCT05460143

Intervention type: OTHER
Intervention: Near-infrared Spectroscopy scan
Description: Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.

Intervention type: OTHER
Intervention: Near-infrared Spectroscopy scan
Description: Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.

Intervention type: OTHER
Intervention: Near-infrared Spectroscopy scan
Description: Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
Study: NCT05099744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrostimulation Therapy
Description: During 20 minutes participants are connected to the handles and receive electrostimulation therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrostimulation Therapy
Description: During 20 minutes participants are connected to the handles and receive electrostimulation therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During 20 minutes participants will be connected to the handles but will not receive any frequency.
Study: NCT05915780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling
Description: The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period

Intervention type: DEVICE
Group type: OTHER
Intervention: Balance Board
Description: Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
Study: NCT05460143

Intervention type: OTHER
Intervention: Near-infrared Spectroscopy scan
Description: Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.

Intervention type: OTHER
Intervention: Near-infrared Spectroscopy scan
Description: Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging scan
Description: Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.